Hikma Pharmaceuticals

Hikma Pharmaceuticals (LSE:HIK) is a fast-growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of branded and non-branded generic and in-licenced products. Hikma's operations are conducted through three businesses: Branded, Injectables and Generics. The company is based principally in the MENA region where it is a market leader, the US and EU. In 2012, Hikma achieved revenue of US$ 1,108.7 million and profit attributable to shareholders of US$ 100.3 million. Founded in 1978 in Jordan, Hikma now comprises 27 manufacturing facilities in 11 countries worldwide. Hikma is committed to the highest quality manufacturing with multiple FDA-approved facilities. Hikma's vision is to demonstrate how strategic objectives of a business can be successfully achieved alongside a sustainable interaction with the natural and social environments of the communities in which it operates. Hikma is one of the founding members of PACI (Partnering Against Corruption Initiative), an offshoot of the World Economic Forum.